Yupelri
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $731,130 | 1,924 | 1,150 |
| 2022 | $3.8M | 26,425 | 10,352 |
| 2021 | $414,107 | 21,133 | 9,108 |
| 2020 | $1.5M | 12,726 | 5,717 |
| 2019 | $2.6M | 25,664 | 8,984 |
| 2018 | $184,323 | 207 | 67 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.4M | 2,776 | 36.5% |
| Unspecified | $3.1M | 378 | 32.8% |
| Food and Beverage | $1.7M | 82,376 | 18.1% |
| Consulting Fee | $562,737 | 484 | 6.0% |
| Travel and Lodging | $427,063 | 2,036 | 4.6% |
| Grant | $139,705 | 3 | 1.5% |
| Education | $32,625 | 20 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $7,250 | 6 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | Mylan Specialty L.P. | $2.6M | 0 |
| Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO) | Mylan Specialty L.P. | $156,689 | 0 |
| Research_A Phase 3b, 28-day, Randomized, Active-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin administered before Nebulized Formoterol Fumarate (PER | Mylan Specialty L.P. | $122,083 | 1 |
| Research_Phase 3b, 28-day, Randomized, Active-Controlled, Parallel Group Study to Evaluate Safety and Tolerability of Nebulized Revefenacin administered before Nebulized Formoterol Fumarate | Mylan Specialty L.P. | $80,032 | 1 |
| PIFR 2 | Mylan Specialty L.P. | $52,500 | 0 |
| Nebulized LAMA Program in a Healthcare System | Mylan Specialty L.P. | $40,000 | 0 |
| REV-3001-A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY OF NEBULIZED REVEFENACIN INHALATION SOLUTION IN CHINESE SUBJECTS WITH MODERATE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). | Mylan Inc. | $3,589 | 0 |
Top Doctors Receiving Payments for Yupelri
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Medford, OR | $3.2M | 396 |
| , D.O | Critical Care Medicine | Port Saint Lucie, FL | $159,811 | 242 |
| , MD | Pulmonary Disease | San Antonio, TX | $136,754 | 185 |
| , M.D | Specialist | Panama City, FL | $83,249 | 157 |
| , M.D | Critical Care Medicine | Rock Hill, SC | $82,338 | 162 |
| , MD | Pulmonary Disease | Franklin, TN | $81,841 | 125 |
| Israel Rubinstein | Critical Care Medicine | Chicago, IL | $79,709 | 140 |
| , MD | Pulmonary Disease | Chapel Hill, NC | $71,753 | 96 |
| , M.D | Sleep Medicine | Munster, IN | $71,472 | 163 |
| , M.D | Internal Medicine | Livingston, NJ | $67,373 | 122 |
| , MD | Internal Medicine | Anderson, SC | $67,141 | 89 |
| , M.D | Internal Medicine | Livonia, MI | $65,570 | 88 |
| , D.O | Internal Medicine | Wynnewood, PA | $64,611 | 138 |
| , DO | Pulmonary Disease | Mesa, AZ | $64,065 | 134 |
| , MD | Critical Care Medicine | Cincinnati, OH | $59,945 | 188 |
| , MD | Internal Medicine | Kenosha, WI | $58,258 | 137 |
| , M.D | Pulmonary Disease | Sacramento, CA | $58,185 | 134 |
| , M.D | Internal Medicine | Corpus Christi, TX | $56,813 | 126 |
| , MD | Pulmonary Disease | Saint Charles, MO | $54,833 | 107 |
| , MD | Sleep Medicine | Louisville, KY | $54,668 | 147 |
| , M.D | Pulmonary Disease | Houston, TX | $53,902 | 105 |
| , M.D | Internal Medicine | Greensboro, NC | $53,030 | 148 |
| , MD | Pulmonary Disease | Winston Salem, NC | $51,288 | 78 |
| , MD | Pulmonary Disease | Los Angeles, CA | $51,216 | 92 |
| Christos Kapogiannis | — | New Bedford, MA | $51,150 | 107 |
Manufacturing Companies
- Mylan Specialty L.P. $9.2M
- Mylan Inc. $70,142
- Mylan Pharmaceuticals Inc. $3,124
- Mylan LLC $2,926
Product Information
- Type Drug
- Total Payments $9.3M
- Total Doctors 22,779
- Transactions 88,079
About Yupelri
Yupelri is a drug associated with $9.3M in payments to 22,779 healthcare providers, recorded across 88,079 transactions in the CMS Open Payments database. The primary manufacturer is Mylan Specialty L.P..
Payment data is available from 2018 to 2023. In 2023, $731,130 was paid across 1,924 transactions to 1,150 doctors.
The most common payment nature for Yupelri is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($3.4M, 36.5% of total).
Yupelri is associated with 7 research studies, including "A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler)" ($2.6M).